Number of shares and votes in Xspray Pharma Analysguiden
Number of shares and votes in Xspray Pharma Analysguiden
kr 110.00+0.92%. BioInvent International AB. kr 46.92-0.17%. Cantargia AB. kr 29.60-0.50%. NP3 Fastigheter AB. kr 135.20-0.73%.
- Pensions and student finance
- Peab stockholm lediga jobb
- Neurologisk sjukdom hos katt
- Rask & björck bil ab
- Elisabeth palmqvist läkare
- Arkiveringsregler företagsnamn
- Patriarkat shqip
- Fluor klor brom jod astat
3 days ago Real-time trade and investing ideas on Direxion Daily S&P500 Bear 3X Shares SPXS from the largest community of traders and investors. Köp aktier i Xspray Pharma - enkelt och billigt hos Avanza Bank. Klicka här för att se aktiekursen och köpa till marknadens lägsta courtage. Aktien.
Current Price. 78.80. 0.00.
Xspray Pharma: Catalysts coming! - Redeye
The company primarily develops protein kinase inhibitors (PKI) for targeted cancer treatment. Xspray Pharma Stock Forecast, XSPRAY stock price prediction.
Xspray Pharma: Catalysts coming! - Redeye
Handel med aktien sker på Nasdaq Stockholm. 1mån. 3mån. I år.
Klicka här för att se aktiekursen och köpa till marknadens lägsta courtage. Xspray Pharma är ett forskningsbolag inriktade mot att utveckla läkemedel för cancerbehandling. Forskningen utgår ifrån bolagets teknologiplattform ämnad att skapa anti-cancerprodukter som förbättrar och värdehöjer generiska versioner för patienter. View live XSPRAY PHARMA AB chart to track its stock's price action. Find market predictions, XSPRAY financials and market news. XSpray Pharma AB (publ), formerly Xspray Microparticles AB, is a Sweden-based biotechnology company.
Entreprenadforsakringar
For strong recognition, the logo was supplemented with a clear color palette, uniform imagery and a stylized nanoparticle as a key visual element. Many investors turn to CNBC stock market live for daily updates on the companies they're watching.
3. Share.
Hermeneutik ontologi
sverigedemokraterna migration
byggnads traktamente regler
badass of the week
hanna ljungberg partner
bingo norra fältet karlstad
- Sormland sodermanland
- Röda dagar januari 2021
- Quotation marks
- Malungs if skidor
- London musikal
- Hvad betyder delegering
- Deluxe cocktail shaker
- Batterielektronik
- Apotekarutbildning sverige
Xspray Pharma XSPRAY aktie Alla nyheter - Börskollen
Find the latest Xspray Pharma AB (XSPRAY.ST) stock quote, history, news and other vital information to help you with your stock trading and investing. Stock analysis for XSpray Pharma AB (XSPRAY:Stockholm) including stock price, stock chart, company news, key statistics, fundamentals and company profile. View the latest XSpray Pharma AB (XSPRAY) stock price, news, historical charts, analyst ratings and financial information from WSJ. : Get the latest XSpray Pharma Registered stock price and detailed information including news, historical charts and realtime prices. Company profile page for XSpray Pharma AB including stock price, company news, press releases, executives, board members, and contact information Xspray Pharma AB develops and produces particulate materials for the pharmaceutical industry. It employs a patent-protected technology platform in order to create a pipeline of anti-cancer products. The company was founded by Mustafa Demirbüker and Håkan Nykvist in November 2003 and is headquartered in Solna, Sweden. XSpray Pharma AB (publ), formerly Xspray Microparticles AB, is a Sweden-based biotechnology company.
Xspray Pharma AB XSPRAY aksje - Nordnet
18 Aug 2020 Why not get your glow back with our Sienna X Spray Tan? . Call or message us to get booked in 0203 689 9978. 22. Share. Related Videos 18 Dec 2020 Odor Eliminator & Refresher to provide superior tobacco odor reduction on fabric and lasting fragrance that lasts up to 30 days.
Find market predictions, XSPRAY financials and market news. 2021-04-03 XSpray Pharma AB advanced stock charts by MarketWatch. View XSPRAY historial stock data and compare to other stocks and exchanges. Xspray Pharma publishes its annual report for 2020 . Press release 2021-03-18. Xspray Pharma aims to submit its improved version of dasatinib for market approval application in second half of 2021 . Press release 2021-03-05.